Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP.

JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print]

PMID:
31486832
2.

A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS.

McMahon M, Contreras A, Holm M, Uechi T, Forester CM, Pang X, Jackson C, Calvert ME, Chen B, Quigley DA, Luk JM, Kelley RK, Gordan JD, Gill RM, Blanchard SC, Ruggero D.

Elife. 2019 Sep 3;8. pii: e48847. doi: 10.7554/eLife.48847. [Epub ahead of print]

3.

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK.

Cancer. 2019 Aug 27. doi: 10.1002/cncr.32463. [Epub ahead of print]

PMID:
31454426
4.

Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.

Boscoe AN, Rolland C, Kelley RK.

J Gastrointest Oncol. 2019 Aug;10(4):751-765. doi: 10.21037/jgo.2019.03.10.

5.

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.

Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R.

Clin Cancer Res. 2019 Jul 30. doi: 10.1158/1078-0432.CCR-18-3341. [Epub ahead of print]

PMID:
31363003
6.

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve.

Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK.

J Hepatocell Carcinoma. 2019 Jun 17;6:93-103. doi: 10.2147/JHC.S206979. eCollection 2019.

7.

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056.

PMID:
31295152
8.

Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.

Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK.

Cancer. 2019 Sep 15;125(18):3234-3241. doi: 10.1002/cncr.32206. Epub 2019 Jun 2.

PMID:
31154669
9.

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.

Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20.

PMID:
31109923
10.

Emerging Role for Systemic Therapy in Earlier Stages of HCC.

Kelley RK.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1407. doi: 10.1016/j.ijrobp.2018.08.062. No abstract available.

PMID:
31014785
11.

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.

Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G.

Liver Int. 2019 Aug;39(8):1468-1477. doi: 10.1111/liv.14113. Epub 2019 Jun 3.

PMID:
30963691
12.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310. doi: 10.6004/jnccn.2019.0019.

PMID:
30959462
13.

Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.

Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, Bowman S, Talevich E, Ferrell LD, Kakar S, Krings G.

J Pathol. 2019 Jun;248(2):164-178. doi: 10.1002/path.5243. Epub 2019 Mar 8.

PMID:
30690729
14.

Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma.

Perez PM, Flavell RR, Kelley RK, Umetsu S, Behr SC.

Clin Nucl Med. 2019 Mar;44(3):e133-e135. doi: 10.1097/RLU.0000000000002452.

PMID:
30624275
15.

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.

Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31.

16.

Cabozantinib in Hepatocellular Carcinoma.

Abou-Alfa GK, Borgman-Hagey AE, Kelley RK.

N Engl J Med. 2018 Oct 4;379(14):1384-1385. doi: 10.1056/NEJMc1810178. No abstract available.

PMID:
30281991
17.

Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.

Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K.

J Gastrointest Cancer. 2018 Jul 30. doi: 10.1007/s12029-018-0147-7. [Epub ahead of print]

PMID:
30058032
18.

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK.

N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.

19.

Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.

Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK.

Oncologist. 2018 Sep;23(9):998-1003. doi: 10.1634/theoncologist.2017-0645. Epub 2018 Apr 5.

20.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

21.

Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ.

Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. doi: 10.1038/nrclinonc.2017.157. Epub 2017 Oct 10. Review.

22.

Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.

Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ.

Mol Imaging. 2017 Jan-Dec;16:1536012117723256. doi: 10.1177/1536012117723256.

23.

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.

Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN.

Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Erratum in: Clin Cancer Res. 2018 Feb 15;24(4):985.

24.

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.

Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M.

Oncologist. 2017 Jul;22(7):804-810. doi: 10.1634/theoncologist.2016-0415. Epub 2017 May 9. Review.

25.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S.

J Natl Compr Canc Netw. 2017 May;15(5):563-573.

26.

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E.

Ann Oncol. 2017 Mar 1;28(3):528-534. doi: 10.1093/annonc/mdw651.

27.

Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.

Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D.

Liver Transpl. 2017 Aug;23(8):1015-1022. doi: 10.1002/lt.24764. Epub 2017 Jun 26.

28.

Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA.

J Natl Compr Canc Netw. 2017 Feb;15(2):219-228. Epub 2017 Feb 10.

29.

Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP.

J Gastrointest Oncol. 2016 Dec;7(6):860-874. doi: 10.21037/jgo.2016.08.04.

30.

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ.

J Gastrointest Oncol. 2016 Dec;7(6):819-827. doi: 10.21037/jgo.2016.11.11. No abstract available.

31.

Biliary cancer: Utility of next-generation sequencing for clinical management.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J.

Cancer. 2016 Dec 15;122(24):3838-3847. doi: 10.1002/cncr.30254. Epub 2016 Sep 13.

32.

A phase II study of axitinib in advanced neuroendocrine tumors.

Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK.

Endocr Relat Cancer. 2016 May;23(5):411-8. doi: 10.1530/ERC-16-0008. Epub 2016 Apr 14.

33.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
34.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

35.

Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.

Kelley RK.

Lancet Oncol. 2015 Oct;16(13):1279-81. doi: 10.1016/S1470-2045(15)00296-X. No abstract available.

36.

A 46-Year-Old Asian Woman With Liver Mass.

Morris GJ, Covey AM, D'Angelica M, Chang DT, Yen Y, Kelley RK, Greenberg H, Tsioulias G.

Semin Oncol. 2015 Oct;42(5):e67-76. doi: 10.1053/j.seminoncol.2015.07.007. Epub 2015 Jul 26. Review. No abstract available.

PMID:
26433558
37.

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.

Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM.

Clin Cancer Res. 2016 Jan 1;22(1):61-8. doi: 10.1158/1078-0432.CCR-15-0979. Epub 2015 Aug 6.

38.

Biliary Tract Cancers: Finding Better Ways to Lump and Split.

Kelley RK, Bardeesy N.

J Clin Oncol. 2015 Aug 20;33(24):2588-90. doi: 10.1200/JCO.2015.61.6953. Epub 2015 Jul 20. No abstract available.

PMID:
26195717
39.

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN.

Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15.

40.

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.

41.

Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.

Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW.

BMC Cancer. 2015 Mar 31;15:206. doi: 10.1186/s12885-015-1195-z.

42.

Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.

Trosman JR, Weldon CB, Kelley RK, Phillips KA.

J Natl Compr Canc Netw. 2015 Mar;13(3):311-8.

43.

Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?

Parks AL, McWhirter RM, Evason K, Kelley RK.

J Gastrointest Cancer. 2015 Jun;46(2):161-5. doi: 10.1007/s12029-015-9690-7. No abstract available.

44.

A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.

Cinar P, Calkins SM, Venook AP, Kelley RK.

Anticancer Res. 2014 Dec;34(12):7357-60.

PMID:
25503172
45.

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ.

Int J Cancer. 2015 Apr 15;136(8):1967-75. doi: 10.1002/ijc.29225. Epub 2014 Sep 29.

46.

Hepatobiliary cancers, version 2.2014.

Benson AB 3rd, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H.

J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82.

PMID:
25099447
47.

Genomic sequencing: assessing the health care system, policy, and big-data implications.

Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB.

Health Aff (Millwood). 2014 Jul;33(7):1246-53. doi: 10.1377/hlthaff.2014.0020.

48.

90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP.

J Gastrointest Cancer. 2014 Jun;45(2):168-80. doi: 10.1007/s12029-013-9566-7.

PMID:
24448917
49.

A review of hepatocellular carcinoma (HCC) staging systems.

Subramaniam S, Kelley RK, Venook AP.

Chin Clin Oncol. 2013 Dec;2(4):33. doi: 10.3978/j.issn.2304-3865.2013.07.05.

50.

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK.

Br J Cancer. 2013 Oct 1;109(7):1725-34. doi: 10.1038/bjc.2013.553. Epub 2013 Sep 10.

Supplemental Content

Loading ...
Support Center